Bailout Brings a Little Credit for Research

Recs

2

Disney Buys Marvel!

David Gardner called it. He’s up 1,334%! See what David’s recommending that you buy NEXT.

Stock Advisor

It's understandable if you missed it. Shoved into the middle of the massive bailout bill that became law last Friday, on page 270 of 451 pages, was an extension of the research and development tax credit. The tax credit expired at the end of last year, but this law reinstates it for this year and extends it through the end of 2009.

I know what you're thinking: "Big deal." But it really is.

The tax credit covers up to 20% of qualified research and development spending. From high-tech companies like Microsoft (Nasdaq: MSFT) and Intel (Nasdaq: INTC) to pharmaceutical companies like Pfizer (NYSE: PFE) and Johnson & Johnson (NYSE: JNJ), and even to Harley-Davidson (NYSE: HOG), the tax credit cumulatively adds $7 billion each year to companies' coffers. Sure, it's no $700 billion bailout, but that's not chump change, either.

Ironically, the companies that could use the cash the most are unprofitable ones like Advanced Micro Devices (NYSE: AMD) and Exelixis (Nasdaq: EXEL), but they won't benefit nearly as much. Because they're not paying income taxes, the tax credits just carry over from year to year.

The expiration of the credit and relatively short extension has to be frustrating for companies. This is the 13th time that Congress has extended the credit since it was set up in 1981. Research and development is the lifeblood of many industries, and most companies likely factor it into the decision on whether to begin work on a project.

Just like tax deductions that you and I get, this tax credit isn't a reason to go out and spend money in and of itself. But, because the companies were likely to spend the money anyway, the gift to industries not directly in need of a bailout should be a welcome benefit.

Closed for 15 months – opening 10 days only! Get notified ahead of time as our expert portfolio manager invests $1 MILLION in the best opportunities from across The Motley Fool’s premium investment services. This is the first open since August 2008, by invitation only. Enter email below.

Pfizer and Johnson & Johnson are Income Investor selections. Pfizer, Microsoft, and Intel are Inside Value selections. Exelixis is a Rule Breakers pick. Try any of our Foolish newsletters today, free for 30 days.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool owns shares of Exelixis. The Fool's disclosure policy wants to take itself as a deduction.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

TD AMERITRADE
more info
ShareBuilder
more info
Power E*Trade

more info
Scottrade
more info
Fool Disclosure

DocumentId: 745855, ~/Articles/ArticleHandler.aspx, 11/10/2009 12:14:01 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

The Must-Read Story on Fool.com
Health-Care Reform: A Tale of Two Chambers

Related Tickers

11/9/2009 4:00 PM
JNJ $60.75 Up +0.45 +0.75%
Johnson & Johnson CAPS Rating: *****
INTC $19.46 Up +0.53 +2.80%
Intel Corp CAPS Rating: ****
MSFT $28.99 Up +0.47 +1.65%
Microsoft Corp CAPS Rating: ***
HOG $27.07 Up +1.34 +5.21%
Harley-Davidson, I… CAPS Rating: **
EXEL $7.05 Up +0.25 +3.68%
Exelixis, Inc. CAPS Rating: *****
PFE $17.43 Up +0.47 +2.77%
Pfizer, Inc. CAPS Rating: ****
AMD $5.21 Up +0.17 +3.37%
Advanced Micro Dev… CAPS Rating: **

Community: Investing Wiki

Term Of The Hour

Borrowing: Borrowing is the process of getting the loan of an asset from another entity usually in return for interest.

Want to learn more or edit this definition?
Click here to read more!